Pharmafile Logo
Pharmafocus logo
Advanced Search
shutterstock_142740349_resize_3

Educating pharma

October 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing educated, funding, medical education, transparency

Originally published in the October issue of Pharmafocus, Sean Murray takes a look at how pharma continues to occupy a key …

Feature
opdivo_1_1

Failure for BMS’ Opdivo in lung cancer trial

October 10, 2016
Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq

Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …

News
roche__tree

Roche’s lung cancer success spells competition for BMS’ Opdivo

October 10, 2016
Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq

Roche’s immune-system booster drug Tecentriq (atezolizumab) may cause trouble in the lung cancer field for leader Bristol-Myers Squibb’s Opdivo according …

News
msd_merck_night_building

MSD’s Keytruda twice as successful against standard therapy for lung cancer

October 10, 2016
Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda

MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …

News
1280px-epi-pen_1

Mylan agrees $465m settlement over EpiPen misclassification

October 10, 2016
Business Services, Medical Communications, Sales and Marketing Heather Bresch, Mylan, Price hike, epipen

In the latest scandal in the EpiPen price hike saga, the US Department of Justice has made claims that the …

News
novartis_building

Novartis’ new drug muscles in on Pfizer’s territory

October 10, 2016
Sales and Marketing Eli Lilly, Novartis, Pfizer, ibrance, ribociclib

A drug developed by Novartis, ribociclib, when combined with an older drug, letrozole, has been shown to reduce risk of progression …

News

Woodley Equipment Company Limited Appoints Declan Boyle

October 7, 2016
clinical research, clinical trials

 

Appointment

NICE recommends Forxiga in Triple Therapy for Diabetes

October 7, 2016
Medical Communications AstraZeneca, Forxiga, NHS, NICE, diabetes, type 2 diabetes

The news of NICE’s approval of the Forxiga comes in a busy week for AstraZeneca. They have sold three drugs, …

News
gsk_china_2_2_0_1

Cancer Research UK receives ‘success payment’ from GlaxoSmithKline

October 7, 2016
Medical Communications GSK, GlaxoSmithKline, University of Manchester, cancer research

CRT and the University of Manchester were rewarded financially for their collaboration developing molecules targeting cancer epigenetics. The agreement between …

News
top_ten_stories

Top Ten articles in the Pharma Industry this week

October 7, 2016
Medical Communications

The beginning of October has seen the failure of big drugs in clinical trials have a big knock-on effect for …

News
astrazeneca_building_white

AstraZeneca sells off third drug in five days

October 7, 2016
Medical Communications AstraZeneca, Cilag GmbH, Johnson & Johnson, Rhinocort Aqua

AstraZeneca have completed a third sell off in the course of one week by divesting rights to Rhinocort Aqua outside …

News

ICU Medical to acquire Pfizer’s global infusion therapy business in $1 billion deal

October 6, 2016
Medical Communications Hospira, ICU medical, Pfizer, acquisition, infusion

The $1 billion deal that will take place as ICU Medical Inc. take over Pfizer’s Hospira Infusion Systems will be …

News

“Incorrect classification” of EpiPen leads to $1 billion bill for US government

October 6, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cost, Heather Bresch, Misclassification, Mylan, Price hike, classification, epipen, price, scandal

Mylan’s EpiPen woes show no sign of abating after CMS (Centers for Medicare and Medicaid Services) released figures that show …

News
sicorbio

Teva to sell Allergan’s UK & Ireland generics business for $770m

October 6, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva

Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.

News
alnylambuilding-750xx1632-918-0-153

Alnylam’s shares plunge by 42% after deaths in clinical trials

October 6, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran

Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …

News
basel_site

Novartis axes 175 jobs globally in operations reshuffle

October 5, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Novartis has announced it is to shut down parts of its research operations in Switzerland and China and cutting 175 …

News
1511671_logo_1456919640

Merck’s Keytruda suffers rejection at hands of NICE

October 5, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda

NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …

News
astrazeneca_plaque

AZ “disappointment” at heart drug failure

October 5, 2016
Research and Development AZ, AstraZeneca, trial failure

AstraZeneca has expressed its disappointment that its heart drug Brilinta (ticagrelor) failed to meet its primary endpoint in a recent …

News
fda_sign_web

FDA warns that certain hepatitis C drugs can have serious side-effects

October 5, 2016
Medical Communications, Research and Development FDA, hepatitis B, hepatitis C

The FDA has issued a warning to patients who are currently taking drugs to treat hepatitis C that they may …

News
1280px-epi-pen_1

Mylan’s promised half-price EpiPen not available until year’s end

October 5, 2016
Research and Development, Sales and Marketing Mylan, epipen

Consumers may have to wait until the end of the year for the half-price EpiPen, months after Mylan originally promised …

News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026